A Phase 2, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Efficacy of Multiple Doses of ONO-2808 in Patients With Multiple System Atrophy (MSA)
Latest Information Update: 05 Jun 2025
At a glance
- Drugs ONO 2808 (Primary)
- Indications Multiple system atrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ono Pharmaceutical
Most Recent Events
- 04 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2023 Status changed from not yet recruiting to recruiting.
- 30 Jun 2023 New trial record